US EditionCurevo Enrolls First Participants in Phase 2 Extension Trial
Summary by Hastings Tribune
1 Articles
1 Articles
All
Left
Center
1
Right
Curevo Enrolls First Participants in Phase 2 Extension Trial
SEATTLE, June 02, 2025 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the enrollment of the first patients in a Phase 2 extension trial…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
